Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1950 2
1954 1
1955 3
1956 3
1957 1
1958 2
1959 1
1960 2
1961 2
1962 1
1965 1
1973 1
1974 1
1975 1
1977 1
1978 1
1979 1
1980 4
1981 1
1982 4
1983 5
1984 4
1985 5
1986 7
1987 8
1988 7
1989 3
1990 5
1991 5
1992 6
1993 5
1994 2
1995 5
1996 5
1997 10
1998 10
1999 15
2000 14
2001 10
2002 15
2003 11
2004 14
2005 14
2006 11
2007 17
2008 9
2009 15
2010 11
2011 14
2012 16
2013 29
2014 14
2015 20
2016 24
2017 42
2018 37
2019 35
2020 41
2021 32
2022 37
2023 34
2024 23

Text availability

Article attribute

Article type

Publication date

Search Results

635 results

Results by year

Filters applied: . Clear all
Page 1
[Cirrhosis of the liver].
Bendtsen F, Larsen FS, Ott P, Vilstrup H. Bendtsen F, et al. Among authors: ott p. Ugeskr Laeger. 2014 Feb 17;176(4):V02130126. Ugeskr Laeger. 2014. PMID: 25095867 Free article. Review. Danish.
Challenges in neoantigen-directed therapeutics.
Lybaert L, Lefever S, Fant B, Smits E, De Geest B, Breckpot K, Dirix L, Feldman SA, van Criekinge W, Thielemans K, van der Burg SH, Ott PA, Bogaert C. Lybaert L, et al. Among authors: ott pa. Cancer Cell. 2023 Jan 9;41(1):15-40. doi: 10.1016/j.ccell.2022.10.013. Epub 2022 Nov 10. Cancer Cell. 2023. PMID: 36368320 Free article. Review.
Cancer vaccines.
Schiller JT, Lowy DR, Frazer IH, Finn OJ, Vilar E, Lyerly HK, Gnjatic S, Zaidi N, Ott PA, Balachandran VP, Dietrich PY, Migliorini D, Vonderheide RH, Domchek SM. Schiller JT, et al. Among authors: ott pa. Cancer Cell. 2022 Jun 13;40(6):559-564. doi: 10.1016/j.ccell.2022.05.015. Cancer Cell. 2022. PMID: 35700704 Free PMC article.
NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021.
Swetter SM, Thompson JA, Albertini MR, Barker CA, Baumgartner J, Boland G, Chmielowski B, DiMaio D, Durham A, Fields RC, Fleming MD, Galan A, Gastman B, Grossmann K, Guild S, Holder A, Johnson D, Joseph RW, Karakousis G, Kendra K, Lange JR, Lanning R, Margolin K, Olszanski AJ, Ott PA, Ross MI, Salama AK, Sharma R, Skitzki J, Sosman J, Wuthrick E, McMillian NR, Engh AM. Swetter SM, et al. Among authors: ott pa. J Natl Compr Canc Netw. 2021 Apr 1;19(4):364-376. doi: 10.6004/jnccn.2021.0018. J Natl Compr Canc Netw. 2021. PMID: 33845460
A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer.
Ott PA, Hu-Lieskovan S, Chmielowski B, Govindan R, Naing A, Bhardwaj N, Margolin K, Awad MM, Hellmann MD, Lin JJ, Friedlander T, Bushway ME, Balogh KN, Sciuto TE, Kohler V, Turnbull SJ, Besada R, Curran RR, Trapp B, Scherer J, Poran A, Harjanto D, Barthelme D, Ting YS, Dong JZ, Ware Y, Huang Y, Huang Z, Wanamaker A, Cleary LD, Moles MA, Manson K, Greshock J, Khondker ZS, Fritsch E, Rooney MS, DeMario M, Gaynor RB, Srinivasan L. Ott PA, et al. Cell. 2020 Oct 15;183(2):347-362.e24. doi: 10.1016/j.cell.2020.08.053. Cell. 2020. PMID: 33064988 Free article. Clinical Trial.
Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma.
Hu Z, Leet DE, Allesøe RL, Oliveira G, Li S, Luoma AM, Liu J, Forman J, Huang T, Iorgulescu JB, Holden R, Sarkizova S, Gohil SH, Redd RA, Sun J, Elagina L, Giobbie-Hurder A, Zhang W, Peter L, Ciantra Z, Rodig S, Olive O, Shetty K, Pyrdol J, Uduman M, Lee PC, Bachireddy P, Buchbinder EI, Yoon CH, Neuberg D, Pentelute BL, Hacohen N, Livak KJ, Shukla SA, Olsen LR, Barouch DH, Wucherpfennig KW, Fritsch EF, Keskin DB, Wu CJ, Ott PA. Hu Z, et al. Among authors: ott pa. Nat Med. 2021 Mar;27(3):515-525. doi: 10.1038/s41591-020-01206-4. Epub 2021 Jan 21. Nat Med. 2021. PMID: 33479501 Free PMC article.
Intralesional Cancer Immunotherapies.
Ott PA. Ott PA. Hematol Oncol Clin North Am. 2019 Apr;33(2):249-260. doi: 10.1016/j.hoc.2018.12.009. Epub 2019 Jan 28. Hematol Oncol Clin North Am. 2019. PMID: 30832998 Review.
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer.
Janjigian YY, Bendell J, Calvo E, Kim JW, Ascierto PA, Sharma P, Ott PA, Peltola K, Jaeger D, Evans J, de Braud F, Chau I, Harbison CT, Dorange C, Tschaika M, Le DT. Janjigian YY, et al. Among authors: ott pa. J Clin Oncol. 2018 Oct 1;36(28):2836-2844. doi: 10.1200/JCO.2017.76.6212. Epub 2018 Aug 15. J Clin Oncol. 2018. PMID: 30110194 Free PMC article. Clinical Trial.
T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028.
Ott PA, Bang YJ, Piha-Paul SA, Razak ARA, Bennouna J, Soria JC, Rugo HS, Cohen RB, O'Neil BH, Mehnert JM, Lopez J, Doi T, van Brummelen EMJ, Cristescu R, Yang P, Emancipator K, Stein K, Ayers M, Joe AK, Lunceford JK. Ott PA, et al. J Clin Oncol. 2019 Feb 1;37(4):318-327. doi: 10.1200/JCO.2018.78.2276. Epub 2018 Dec 13. J Clin Oncol. 2019. PMID: 30557521 Clinical Trial.
635 results